Literature DB >> 10334799

Diabetes and cardiovascular events in hypertensive patients.

M H Alderman1, H Cohen, S Madhavan.   

Abstract

To determine the relation of self-reported history of diabetes as well as baseline and in-treatment blood sugar to subsequent cardiovascular disease (CVD) in treated hypertensive patients, we assessed the experience of 6886 participants in a systematic treatment program. The presence or absence of a history of diabetes was known for all patients, who were then stratified into 3 groups according to blood sugar at baseline and in treatment (<6.11, 6.11 to 7.74, and >/=7.75 mmol/L). Some 7.4% of all patients reported history of diabetes, and the overall prevalence of blood sugar >/=7. 75 mmol/L was 7.7% and 10.4% at baseline and in treatment, respectively. Patients with a history of diabetes were 10 or 8 times as likely to have blood sugar >/=7.75 mmol/L at baseline (47.2% versus 4.5%) or in treatment (55.0% versus 6.8%), as were patients without history. During an average 6.3 years of follow-up, patients with history of diabetes had a cardiovascular event incidence 2-fold higher than those without history (20.8 versus 8.6/1000 person-years). Age-gender-adjusted CVD incidence rate but not non-CVD was twice as high in the highest compared with the lowest blood sugar stratum (baseline 16.6 versus 8.4/1000 person-years; in treatment 15.2 versus 8.2). Three separate models of Cox multivariate analysis revealed that history of diabetes (with no history as reference) had a greater association with CVD events (hazard ratio 2.37, 95% confidence interval 1.80 to 3.11) than did baseline (1.75, 1.31 to 2.33) or in-treatment blood sugar (1.55, 1. 19 to 2.02). Furthermore, in the presence of history of diabetes (2. 15, 1.58 to 2.92), neither baseline nor in-treatment blood sugar was independently associated with CVD risk. In the elevated (>/=7.75 mmol/L) in-treatment blood sugar group, the age-gender-adjusted rate of CVD events in frequent diuretic users (30.79/1000 person-years) was significantly higher than in moderate (13.34, P=0.004) and rare users (13.25, P=0.008). These data affirm that the coincidence of diabetes and hypertension is common, that evidence of diabetes substantially increases CVD risk, that self-reported history is a more powerful predictor of CVD events than any measure of blood sugar, and that CVD increases in hypertensive diuretic users who develop hyperglycemia even when blood pressure is well controlled.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334799     DOI: 10.1161/01.hyp.33.5.1130

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  33 in total

1.  Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography.

Authors:  Peifeng Dai; Junhua Wang; Lin Lin; Yanyan Zhang; Zhengping Wang
Journal:  Exp Ther Med       Date:  2015-06-22       Impact factor: 2.447

Review 2.  Prediabetes and cardiovascular risk in hypertensive patients.

Authors:  Julian Segura; Cecilia Roldán; Jose A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

3.  Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.

Authors:  Jason H Karnes; Yan Gong; Michael A Pacanowski; Caitrin W McDonough; Meghan J Arwood; Taimour Y Langaee; Carl J Pepine; Julie A Johnson; Rhonda M Cooper-Dehoff
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

Review 4.  Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese.

Authors:  Yukako Tatsumi; Takayoshi Ohkubo
Journal:  Hypertens Res       Date:  2017-07-13       Impact factor: 3.872

Review 5.  Statins and blood pressure regulation.

Authors:  C Borghi; M Veronesi; M G Prandin; A Dormi; E Ambrosioni
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

6.  Hypertension and combinations of cardiovascular risk factors. An epidemiologic case-control study in an adult population in Guadeloupe (FWI).

Authors:  L Foucan; J Bangou-Brédent; D K Ekouévi; J Deloumeaux; J E Roset; P Kangambega
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 7.  Lessons from trials in hypertensive type 2 diabetic patients.

Authors:  Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

8.  Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.

Authors:  J H Karnes; C W McDonough; Y Gong; T T Vo; T Y Langaee; A B Chapman; J G Gums; A L Beitelshees; K R Bailey; J L Del-Aguila; E A Boerwinkle; C J Pepine; S T Turner; J A Johnson; R M Cooper-DeHoff
Journal:  Pharmacogenomics J       Date:  2012-08-21       Impact factor: 3.550

9.  Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.

Authors:  Shinji Yasuno; Kenji Ueshima; Koji Oba; Akira Fujimoto; Masakazu Hirata; Toshio Ogihara; Takao Saruta; Kazuwa Nakao
Journal:  Diabetes Care       Date:  2010-02-25       Impact factor: 19.112

Review 10.  Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.

Authors:  J N Basile
Journal:  Int J Clin Pract       Date:  2009-02-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.